Pulmonary Embolism Subacute Massive Clinical Trial
Official title:
The Impact of System Wide Pulmonary Embolism Screening Program on PERT Activation, Utilization of Advanced Therapies, and 90-Day Outcomes
Pulmonary embolism (PE) remains a high mortality and morbidity disease state. We have previously shown that use of a Pulmonary Embolism Response Team (PERT) can improve overall readmission, bleeding, and mortality outcomes. Unfortunately, PERT may still be underutilized from a national standpoint and may not be readily available in underserved areas. The utility of the current study is to investigate the implementation of an artificial intelligence (AI) program to differentiate patients at the highest risk of the PE spectrum to help efficiently identify those most appropriate for aggressive management. Furthermore, we will investigate the utility of an algorithm-driven protocol for activation of invasive interventions versus traditional PERT discussion and evaluate overall patient outcomes.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04996667 -
Effect of iNO in Patients With Submassive and Massive PE
|
Phase 2 | |
| Terminated |
NCT03988842 -
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
|
Phase 4 | |
| Enrolling by invitation |
NCT04855370 -
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE
|
N/A | |
| Not yet recruiting |
NCT05612854 -
Catheter Directed Therapy in Intermediate Risk Pulmonary Embolism Patients
|
Early Phase 1 |